Literature DB >> 27847642

The role of optical coherence tomography in Alzheimer's disease.

Leonardo Provetti Cunha1, Ana Laura Maciel Almeida2, Luciana Virgínia Ferreira Costa-Cunha3, Carolina Ferreira Costa3, Mário L R Monteiro4.   

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia and its incidence is increasing worldwide along with population aging. Previous clinical and histologic studies suggest that the neurodegenerative process, which affects the brain, may also affect the retina of AD patients. MAIN BODY: Optical coherence tomography (OCT) is a non-invasive technology that acquires cross-sectional images of retinal structures allowing neural fundus integrity assessment. Several previous studies demonstrated that both peripapillary retinal nerve fiber layer and macular thickness measurements assessed by OCT were able to detect neuronal loss in AD. Moreover, recent advances in OCT technology, have allowed substantial enhancement in ultrastructural evaluation of the macula, enabling the assessment not only of full-thickness retinal measurements but also of inner retinal layers, which seems to be a promising approach, mainly regarding the assessment of retinal ganglion cell layer impairment in AD patients. Furthermore, retinal neuronal loss seems to correlate with cognitive impairment in AD, reinforcing the promising role of OCT in the clinical evaluation of these patients.
CONCLUSION: The purpose of this article is to review the main findings on OCT in AD patients, to discuss the role of this important diagnostic tool in these patients and how OCT technology may be useful in understanding morphological retinal changes in AD.

Entities:  

Keywords:  Alzheimer’s disease; Dementia; Ganglion cell layer; Macula; Mild cognitive impairment; Optic nerve; Optical coherence tomography; Retina; Retinal nerve fiber layer

Year:  2016        PMID: 27847642      PMCID: PMC5088456          DOI: 10.1186/s40942-016-0049-4

Source DB:  PubMed          Journal:  Int J Retina Vitreous        ISSN: 2056-9920


Background

Alzheimer’s disease (AD) is the most common cause of dementia and its incidence is increasing worldwide associated with population aging [1]. AD is characterized by progressive cognitive impairment, such as memory deficit, decline in learning and executive functioning, aphasia, apraxia, agnosia and visual abnormalities [2, 3]. Visual complaints are common findings in AD patients and these may have an important impact on autonomy and quality of life of these patients. The most common visual symptoms are impairment of spatial contrast sensitivity, motion perception, color discrimination and visual loss, which in the past, were attributed to lesions affecting the primary visual cortex and other specific areas of the brain [3-6]. Neuroimaging techniques are essential in the diagnosis of AD and magnetic resonance imaging (MRI) has become the most used tool for cerebral imaging in AD patients, providing detailed information about brain structure. The most common findings in MRI of patients with AD are atrophy in the medial temporal lobe, including hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus, ventricular enlargement and reduction of total brain volume [7]. Although studies have not yet completely elucidated the structural and functional changes that occur in brains of AD patients, some clinical and histologic studies suggest that the same neurodegenerative process that occurs in the brain, may also affect the retina, since the latter represents a peripheral part of central nervous system. Retinal pathological changes such as loss of retinal ganglion cell (RGC) and their axons were demonstrated, both in animal models and in post mortem studies of human AD eyes [8-11]. Toxic aminoacids, such as fibrillar tau and Aβ aggregates were accumulated within the retina and its microvasculature, and signs of neuroinflammation were present in the retina [12-16]. Therefore, according to several clinical and histologic studies there is strong evidence of anterior visual pathway impairment in AD patients, with predominant involvement of RGC and their fibers [10, 11, 17–19]. Optical coherence tomography (OCT) is a non-invasive technology, which acquires cross-sectional images of retinal structures allowing neural fundus integrity assessment. Over the last years, OCT became the most widely used technology to detect and quantify structural axonal damage in many optic nerve and neurological diseases. Axonal loss is usually quantified by measuring OCT peripapillary retinal nerve fiber layer (RNFL) that allows an indirect estimation of RGC layer impairment. Furthermore, neuronal loss can be directly accessed by estimating macular thickness measurements, since 30–35 % of the retina thickness in macular area is composed by the RGCs and their fibers, as previously demonstrated in eyes with glaucoma, papilledema, compressive or demyelinating optic neuropathies [20-22]. If we take into account that the retina is considered a peripheral extension of the brain and both share similar embryological origin, it is easy to understand why OCT has become a widespread diagnostic tool in many neurological diseases. Therefore, the purpose of this article is to address the main findings on OCT in AD patients, to discuss the role of this important diagnostic tool in these patients and how OCT technology could be useful to understand morphological retinal changes in AD.

Peripapillary retinal nerve fiber layer thickness in Alzheimer’s disease patients

The degeneration of the optic nerve and consequent loss of ganglion cells and their axons was first demonstrated histologically in patients with AD around 30 years ago [10]. Other studies confirmed these findings, revealing a predominant loss of the largest RGCs (M-cells) [11]. These post-mortem studies are clear evidence of anterior visual pathway impairment in AD patients. Hedges et al. [23] evaluated fundus photographs from 26 AD patients and found a high incidence of RNFL abnormalities. With the advent of OCT, over the last two decades, it became possible to provide a directly clinical quantitative assessment of retinal axonal loss. Several previous studies have evaluated the peripapillary RNFL thickness measurements assessed by OCT and all of them were able to demonstrate that most of RNFL parameters were reduced in patients with AD [19, 24–34]. The reduction of RNFL thickness was significantly greater than that which is observed in the age-matched controls and thus cannot be exclusively ascribed to aging. In accordance with these studies, the reduction of RFNL thickness occurred in each of the four retinal quadrants, suggest that axonal loss in patients with AD seems to be the result of a diffuse degeneration process of RGCs. Global reduction of peripapillary RNFL average thickness measurements in AD patients was demonstrated by several independent groups [24, 28, 30, 31, 34]. Most of them observed a significant reduction of RNFL thickness in all quadrants [19, 24, 31, 35, 36], with a predominance in the superior [26-30] and inferior quadrants [24, 27, 30]. Different groups showed the axonal loss with RNFL reduction in AD patients, despite different commercially available OCT devices used [37, 38]. Thomson et al. [39] conducted a systematic review and meta-analysis of the literature to determine the diagnostic utility of OCT of the RNFL thickness measurements in various dementias, but focused predominantly in patients with AD and mild cognitive impairment (MCI). They included studies published until September 2014. They identified a total of 17 studies including 702 AD eyes and 790 control eyes. There was a significant reduction in the overall, inferior and temporal RNFL thickness measurements in AD patients compared with controls, regardless of whether time domain (TD) or spectral domain (SD) OCT was used. The nasal and temporal quadrants are only found to be significantly thinner in few studies. These authors concluded that studies analyzed in the systematic review suggest that the significant thinning of the RNFL does occur in AD, and that OCT can be successfully used to detect these changes. In our review, we identified a total of 23 studies including 1330 AD eyes, 326 MCI eyes and 1082 control eyes. In nine studies TD-OCT was used and in the other fourteen, the patients were evaluated by SD-OCT. Seven studies included MCI [25, 28, 34, 35, 40–42] patients and others nine evaluated macular parameters [24–26, 31, 35, 40, 43–45]. Table 1 summarizes the demographic data and RNFL thickness measurements in Alzheimer’s disease, MCI and controls by OCT.
Table 1

Demographic data and retinal nerve fiber layer thickness measurements in Alzheimer’s disease, mild cognitive impairment and controls by OCT

StudyOCT typeDiagnosis, number of subjects (eyes)Mean age ± SD (years)Mean MMSE ± SDMean peripapillary RNFL SD (µm)Notes
Parisi et al. [19]TDAD, 17 (17)70.4 ± 6.116.4 ± 2.459.5 ± 16.8**The mean peripapillary RNFL thicknes correlated with PERG
Controls, 14 (14)Age-matched99.9 ± 8.95
Iseri et al. [26]TDAD, 14 (28)70.1 ± 9.718.5 ± 6.387.5 ± 23.8***The peripapillary and macular RNFL thickness of AD patients were thinner than in control subjects. Total macular volume and MMSE scores were significantly correlated
Controls, 14 (14)65.1 ± 9.8113.2 ± 6.7
Berisha et al. [46]TDAD, 9 (9)74.3 ± 3.323.8 ± 5.185.5 ± 7.4Narrow veins and decreased retinal blood flow in these veins
Controls, 8 (8)74.3 ± 5.893.8 ± 10.4
Paquet et al. [34]TDAD, 26 (52)78.5 ± 4.983.4 ± 7.2**Early involvement of the RNFL in patients with MCI
 Mild AD, 14 (28)22.6
 Severe AD, 12 (24)16.6
MCI, 23 (46)78.7 ± 5.128.889.3 ± 2.7**
Controls, 15 (30)75.5 ± 5.1102.2 ± 1.8
Lu et al. [30]TDAD, 22 (44)73.0 ± 8.090.0 ± 18.0*The RNFL thickness reductions of predominantly in the superior and inferior quadrants
Controls, 22 (44)68.0 ± 9.098.0 ± 12.0
Kesler et al. [27]TDAD, 30 (52)73.7 ± 9.923.6 ± 4.384.7 ± 10.6*No correlation between RNFL thickness measurements and MMSE in AD patients
MCI, 24 (40)71.0 ± 10.028.1 ± 2.185.8 10.0*
Controls, 24 (38)70.9 ± 9.294.3 ± 11.3
Moschos et al. [33]TDAD, 30 (60)71.8 ± 8.6There is a functional abnormality of the outer retina in central macular area in mild stages of AD
Controls, 30 (60)Age-matched
Moreno-Ramos et al. [32]SDAD, 10 (20)73.0 ± 6.516.494.5 ± 2.2*The RNFL thickness correlated significantly with both the MMSE and the Mattis Dementia Rating Scale scores in AD patients
Controls, 10 (20)70.0 ± 2.0108.0 ± 2.2
Marziani et al. [31]SDAD, 21 (21)79.3 ± 5.719.9 ± 3.1Macular RNFL and RNFL + GCL thickness measurements are reduced in AD patients compared with healthy subjects
Controls, 21 (21)77.0 ± 4.2
Kirbas et al. [28]SDAD, 40 (80)69.3 ± 4.921.465.0 ± 6.2*No correlation between OCT parameters and MMSE
Controls, 40 (80)68.9 ± 5.175.0 ± 3.8
Larrosa et al. [47]SDAD, 151 (151)75.318.397.5 ± 14.1Used two different OCT (cirrus and spectralis)
Controls, 61 (61)74.9100.6 ± 13
Ascaso et al. [35]TDAD, 18 (36)72.1 ± 8.7 (AD + aMCI)19.3 (AD + aMCI)64.7 ± 15.2The increased thickness and macular volume in aMCI
aMCI, 21 (42)72.1 ± 8.7 (AD + aMCI)19.3 (AD + aMCI)86.7 ± 7.18***
Controls, 41 (82)72.9103.1 ± 8.04
Polo et al. [45]SDAD, 75 (75)74.116.097.4 ± 11.2 (cirrus); 98.1 ± 10.7 (spectralis)SD-OCT protocols were able to detect RNFL and macular atrophy in AD patients
Controls, 75 (75)73.999.2 ± 9.9 (cirrus); 101.6 ± 9.5 (spectralis)
Kromer et al. [29]SDAD, 22 (42)75.9  ±  6.1 22.6  ±  5.5104.3 ± 17.5AD patients with mild to moderate stages of showed a significant reduction of RNFL thickness in the nasal superior sector
Controls, 22 (42)64.0 ± 8.2101.8 ± 10.7
Bambo et al. [48]SDAD, 56 (56)74.0 ± 8.116.689.4 ± 10.4**Presence of optic disc pallor correlate with axonal loss and perfusion alterations in AD
Controls, 56 (56)76.4 ± 8.4100.9 ± 11.7
Bayhan et al. [43]SDAD, 31 (31)75.8  ±  6.517.4  ±  4.9A significant correlation with the macular GCC parameters and MMSE scores in AD patients
Controls, 30 (30)74.9 ± 7.6
Liu et al. [41]TDAD, 67 (134)The RNFL thickness in the superior quadrant and total mean values are gradually and significantly decreased from MCI to severe AD
 Mild AD, 2471.3 ± 4.991.6 ± 10.1*
 Moderate AD, 2470.8 ± 691.7 ± 12.4*
 Severe AD, 1972.1 ± 4.687.1 ± 17.1***
MCI, 26 (52)70.2 ± 6.595.4 ± 17.1
Controls, 39 (78)69.7 ± 7.8100.1 ± 15
Gao et al. [25]SDAD, 25 (50)74.7 ± 1.319.2 ± 0.686 ± 1.9**Reduced macular volume in AD and MCI patients, no correlation between MMSE and OCT parameters
aMCI, 25 (50)73.4 ± 1.525.8 ± 0.3592.4 ± 1.9*
Controls, 21 (42)72.1 ± 198.6 ± 1.7
Oktem et al. [49]SDAD, 35 (70)75.4 ± 6.918.080.6 ± 9.6***RNFL thickness measurements can be useful for early diagnosis and evaluation of disease progression
MCI, 35 (70)74.1 ± 6.328.082.5 ± 7.3
Controls, 35 (70)70.2 ± 8.029.091.5 ± 7.1
Salobrar-Garcia et al. [50]SDAD, 23 (23)79.3 ± 4.623.3 ± 3.1Increase in peripapillary thickness in mild-AD patients
Controls, 28 (28)72.3 ± 5.1
Cunha et al. [24]SDAD, 24 (45)74.8 ± 6.217.0 ± 5.293.7 ± 13.4Neuronal loss, especially for macular parameters, correlated well with cognitive impairment in AD
Controls, 24 (48)72.3 ± 7.3103 ± 9.2
Garcia-Martin et al. [51]SDAD, 150 (150)75.3318.35 ± 3.3395.7 ± 15.22Performed segmentation of all retinal layers. Inner retinal layers reduction may predict greater disease severity
Controls, 75 (75)74.7999.23 ± 16.48
Choi et al. [40]SDAD, 42 (42)76.8 ± 8.714.5 ± 5.5Performed segmentation of all retinal layers
MCI, 26 (26)74.7 ± 7.823.1 ± 4.686.6 ± 10.2
Controls, 66 (66)73.8 ± 7.5

AD Alzheimer’s disease, MCI mild cognitive impairment, aMCI amnestic mild cognitive impairment, RNFL retinal nerve fiber layer, OCT optical coherence tomography, SD standard deviation, TD time-domain, SD (OCT type column) spectral domain, MMSE mini mental state examination, PERG pattern-reversal electroretinogram, GCL ganglion cell layer, GCC ganglion cell complex

* P < 0.05; ** P < 0.01; *** P < 0.001 when compared to controls

Demographic data and retinal nerve fiber layer thickness measurements in Alzheimer’s disease, mild cognitive impairment and controls by OCT AD Alzheimer’s disease, MCI mild cognitive impairment, aMCI amnestic mild cognitive impairment, RNFL retinal nerve fiber layer, OCT optical coherence tomography, SD standard deviation, TD time-domain, SD (OCT type column) spectral domain, MMSE mini mental state examination, PERG pattern-reversal electroretinogram, GCL ganglion cell layer, GCC ganglion cell complex * P < 0.05; ** P < 0.01; *** P < 0.001 when compared to controls

Macular thickness measurements in Alzheimer’s disease patients

Since the RGCs layer and their axons contribute with approximately one-third of the total retinal thickness in macular area, macular thickness measurements assessed by OCT can be used to investigate neuronal loss in AD patients. This approach in AD evaluation is promising, first because RGC’s and their fibers are located in macular area, which in accordance with previous histopathological studies, are preferably affected in AD [8, 9, 17], and secondly, because of the significant improvements occurred in the latest OCT’s equipments, evolving from time-domain (TD) to spectral fourier domain technology [52]. These improvements on OCT technology provide three-dimensional high-quality images with greater resolution, with an axial resolution up to five times higher and imaging speeds approximately 60 times greater than earlier TD OCT [53, 54]. This high-density raster retinal tissue scanning allow to detect and segment the retinal structures in each raster OCT image and use these data to construct a detailed macular map, with separate analysis of different retinal layers [52].

Full thickness macular measurements

Iseri et al. [26] were the first group to assess both macular thickness and volume by TD-OCT of 28 eyes of 14 patients with AD. The retinal thickness in all macular quadrants of AD patients was lower than in control subjects and reached statistical significance in the nasal, temporal and inferior quadrants, as well to the mean total macular volume. Moschos et al. [33] also evaluated the macular parameters using TD-OCT in AD patients. They demonstrated a preferential involvement of the central macular area. In SD-OCT era, Polo et al. [45] evaluated macular area by SD-OCT of 75 AD patients and 75 age-matched healthy subjects. Retinal thinning was observed in AD eyes in all areas except from the fovea. In other study, Gao et al. [25] evaluated 25 patients with AD and found a significant reduction of macular volume in these patients. Salobrar-Garcia et al. [50] also demonstrated a preferential reduction of macular parameters in mild-AD patients. In this study, the peripapilary RNFL thickness was thinner, but did not reach a significant difference compared with age-matched controls, suggesting a preferential involvement of the macula in early stages of the disease. In a recently published study [24], we have evaluated 45 eyes of 24 patients with AD using SD-OCT. Our results showed that the macula full-thickness measurements were significantly reduced in all segments, except in the inferior outer segment. The inner segments, around the fovea, were the most affected (Figs. 1, 2). This was an interesting finding and possibly indicates a pattern of neuronal loss in patients with AD. In agreement with our findings, Blank et al., in a histologically analysis, observed a total decrease of one quarter of neurons in GCL at the level of the fovea and parafoveal area of the retina in AD patients [9].
Fig. 1

Examples of Topcon 3D OCT-2000 generated full-thickness macular measurements in the right (OD) and left (OS) eye of a patient with Alzheimer’s disease. Measurements in different sectors are indicated with numbers and represented in colors that correspond to the normal distribution. Sectors in green indicate values within normal range; in yellow less than the 5th, in red less than the 1st compared with an age-matched reference population. Note that several macular thickness parameters are below normal range, particularly in inner segments

Fig. 2

A print out of inner macular analysis using SD-OCT in a patient with Alzheimer disease. The built-in viewer shows the color retinography, oct line scan, macular RNFL thickness (mRNFL), the ganglion cell layer + inner plexiform layer (GCL+) thickness, and the RNFL + GCL + IPL (GCL++) thickness. a Fundus color. The green square line demarcates the macular area scanned (7 × 7 mm) by the FD-OCT. b Optical coherence tomography (vertical scan) of macular area. Center pseudo-colored map of the measured thickness. Lower each grid in the 10 × 10 grid was color coded with no color (within the normal limit), yellow (outside of the 95 % normal limit), or red (outside of the 99 % normal limit)

Examples of Topcon 3D OCT-2000 generated full-thickness macular measurements in the right (OD) and left (OS) eye of a patient with Alzheimer’s disease. Measurements in different sectors are indicated with numbers and represented in colors that correspond to the normal distribution. Sectors in green indicate values within normal range; in yellow less than the 5th, in red less than the 1st compared with an age-matched reference population. Note that several macular thickness parameters are below normal range, particularly in inner segments A print out of inner macular analysis using SD-OCT in a patient with Alzheimer disease. The built-in viewer shows the color retinography, oct line scan, macular RNFL thickness (mRNFL), the ganglion cell layer + inner plexiform layer (GCL+) thickness, and the RNFL + GCL + IPL (GCL++) thickness. a Fundus color. The green square line demarcates the macular area scanned (7 × 7 mm) by the FD-OCT. b Optical coherence tomography (vertical scan) of macular area. Center pseudo-colored map of the measured thickness. Lower each grid in the 10 × 10 grid was color coded with no color (within the normal limit), yellow (outside of the 95 % normal limit), or red (outside of the 99 % normal limit)

Inner retinal layers in Alzheimer’s disease patients

In the last decade, the spectral OCT technology evolved significantly allowing for creating high-resolution cross-sectional images. The acquisition speed in SD-OCT reduced the time to acquire three-dimensional images with higher resolution, enhancing the ultrastructural macula analysis, enabling the assessment not only of full macular thickness measurements but also of inner retinal layers. These layers are of particular interest in many ocular and neurological diseases and recent studies based on OCT measurements have demonstrated that the presence of RGC loss may be an early indicator of neural loss in many conditions, such as glaucoma, papilledema, compressive optic neuropathy, multiple sclerosis and optic neuromyelitis [55-58]. This approach may be promising in AD evaluation, especially because the RGC impairment shares similarities with neuronal loss in the brains of these patients. In fact, the reduction of full macular thickness, as shown in previous studies, is possibly related to the preferential involvement of the ganglion cell layer (GCL) [25, 26, 33, 45]. In 2013, Marziani et al. [31] using SD-OCT, demonstrated a reduction of RNFL + GCL thickness in the nine ETDRS subfields map in AD patients compared with age-matched controls. With the same SD-OCT, another group [43] demonstrated that the average, superior and inferior GCL thickness of the AD patients were significantly thinner than those of the controls. Cheung et al. [59] showed a significantly reduced macular ganglion cell-inner plexiform layer thicknesses in all macular sectors in AD patients compared with cognitively normal controls. In our study [24], the inner macular layers thickness measurements were automatically registered in a square pattern (6 × 6 mm). In each B-scan, the boundaries between the anatomical inner retinal layers in macular area were automatically delimited by built-in software (Fig. 3). The parameters registered in this study were: the average of macular retinal nerve fiber layer (mRNFL) thickness, the average of GCL plus the inner plexiform layer (IPL) thickness, referred as GCL+ and the average of RNFL plus GCL+ thickness, referred as GCL++ (Fig. 3). A pseudo-color thickness map of these layers is shown in Figs. 2 and 3. Our results demonstrate that the GCL+ and GCL++ thickness were significantly lower in eyes of AD patients. The mRNFL thickness measurements in AD eyes were lower than in control eyes, but did not reach statistical significance. Our results demonstrated that inner retinal layers impairment reflect the neuronal degeneration of the retina in AD patients, predominantly affecting the central macular area.
Fig. 3

Example of inner macular thickness measurements by SD-OCT of AD patient. On the left (a, c, e) represents the scanned area (7 × 7 mm). Each 10 × 10 grid was color coded with no color (within the normal limit), yellow (outside the 95 % normal limit), or red (outside the 99 % normal limit). The total analyzed area corresponding to 6 × 6 mm. On the right vertical OCT scans through the fovea. The white lines correspond to the boundaries of the inner retinal layers identified during the segmentation process. b Macular RNFL (mRNFL) thickness measurement, through the internal limiting membrane (ILM) to inner boundary of ganglion cell layer (GCL). d GCL plus inner plexiform layer (IPL), through the inner boundary of GCL to outer boundary of IPL (GCL+). f mRNFL plus GCL plus IPL, trough the ILM to outer boundary of IPL (GCL++)

Example of inner macular thickness measurements by SD-OCT of AD patient. On the left (a, c, e) represents the scanned area (7 × 7 mm). Each 10 × 10 grid was color coded with no color (within the normal limit), yellow (outside the 95 % normal limit), or red (outside the 99 % normal limit). The total analyzed area corresponding to 6 × 6 mm. On the right vertical OCT scans through the fovea. The white lines correspond to the boundaries of the inner retinal layers identified during the segmentation process. b Macular RNFL (mRNFL) thickness measurement, through the internal limiting membrane (ILM) to inner boundary of ganglion cell layer (GCL). d GCL plus inner plexiform layer (IPL), through the inner boundary of GCL to outer boundary of IPL (GCL+). f mRNFL plus GCL plus IPL, trough the ILM to outer boundary of IPL (GCL++) So, as previously demonstrated, the inner retinal layers seem to be preferentially affected in AD. However, information about the integrity of the other retinal layers is crucial. Recent advances in the SD-OCT technology, particularly with improvements in segmentation software analysis, may allow the measurement of all retinal layers. In a recently published study, Garcia-Martin et al. [51], using an automatic segmentation prototype, showed that not only inner retinal layers were reduced in AD patients, but the outer nuclear layers were also impaired. Studies are needed in order to verify the clinical significance of this finding in AD patients and if it’s an indicative of a diffuse degenerative process affecting all retinal layers or as result of retrograde transinaptic degeneration.

Correlation between RNFL and macular thickness measurements with the cognitive impairment in Alzheimer’s disease patients

Some of the crucial approaches for diagnosis of AD are based on neuropsychological tests such as the mini-mental state examination (MMSE) scores, which are widely used to evaluate the cognitive impairments in dementia patients [2]. So, since the measurement of the degree of severity of cognitive impairment can be given by MMSE score, it seems reasonable that the correlation between this psychological test and OCT parameters could be useful information for clinical evaluation and monitoring of these patients. In fact, some previous studies have evaluated the correlation between OCT and MMSE score, but the results are somewhat conflicting. While some authors failed to demonstrate a significant correlation between the OCT parameters and MMSE scores [25, 27, 45], others have shown opposite results. Iseri et al. [26] were the first to demonstrate a significant correlation between OCT parameters and MMSE scores in AD patients. However, the correlation was significant only for the total macular volume, and not for the peripapillary RNFL thickness measurements. On the other hand, Ascaso et al. [35] showed a significant association between RNFL thickness in superior and inferior quadrants, and MMSE score. Oktem et al. [42] also demonstrated a significant correlation between MMSE scores and the RNFL parameters. Recently, our group confirmed a significant correlation between MMSE scores and several SD-OCT parameters [24]. For peripapillary RNFL parameters, a significant correlation was found for the average, superior and inferior thickness. For the macular thickness, all parameters (except the superior and inferior outer segments) showed significant correlation with MMSE scores. The most significant correlations were those of the four (superior, inferior, nasal and temporal) inner macular segments and GCL++, reflecting the most affected parameters in our patients. In accordance to our results, Bayhan et al. [43] also demonstrated a significant correlation between MMSE scores and macular GCL thickness. The correlation between cognitive impairment and OCT parameters seems to be stronger for both full macular thickness and inner retinal layers. This is in agreement with the post mortem histological study in eyes of AD patients which demonstrated a predominantly RGC loss at the level of the fovea and parafoveal retina [9]. Therefore, macular thickness assessment using OCT, especially with the advances in high-resolution SD-OCT equipments, seems to be a promising diagnostic tool in AD patients. However, further studies, including earlier stages of the disease and monitoring OCT parameters changes along the course of the disease, are required.

Optical coherence tomography parameters in mild cognitive impairment

The MCI is a clinical condition in which the individual presents with memory loss, larger than expected for their age, but not enough to impair their daily activities [60]. The MCI can be considered as an intermediate stage between normal aging and dementia [61]. The amnestic MCI (aMCI), a subtype with a predominant memory impairment, can be considered by many authors as an early stage of AD, mainly because the rate of progression to Alzheimer in aMCI is 10–15 % per year, while in normal individuals, the conversion rate is only 1–2 % per year [61, 62]. Since MCI may represent an earlier stage of dementia, before the onset of the AD, it is important that these patients undergo careful medical evaluation over the years. Monitoring the clinical status and using ancillary objective tests that could document possible progression to AD are also required. In this scenario, the RNFL thickness and macular measurements by OCT may turn out to represent a non-invasive in vivo biological marker in both MCI and AD patients. Paquet et al. [34] demonstrated that the mean peripapilary RNFL were reduced in both MCI and AD patients, but no significant differences were found between MCI and AD parameters. Similar results were also demonstrated by Oktem et al. [42]. On the other hand, another group found that the total RNFL thickness of MCI patients was significantly different of both AD (thinner) and controls (thicker). The peripapillary RNFL loss was more pronounced in inferior quadrant [27]. Ascaso et al. [35] evaluated peripapillary RNFL thickness and both macular thickness and volume in MCI patients by OCT, and also confirmed a reduction of mean RNFL thickness measurements and in all except from the nasal quadrant when compared to controls. Moreover, these authors found an apparently conflicting data, an increase in macular thickness parameters of MCI patients. They attributed this finding to possible inflammation and/or gliosis that would occur in the early stages of AD. In a recently published study using SD-OCT, Gao et al. [25] found that the average thickness of the RNFL was reduced in MCI patients compared to AD patients (at inferior quadrant and segments of 5 and 6 o’clock). Compared to controls, MCI patients showed a significant reduction in RNFL thickness measurements only in the temporal quadrant and segments of 8, 9 and 10 o’clock. They also found significant reduction of the macular volume in MCI patients. Other authors showed that the RNFL thickness measurements were reduced in the superior quadrant and the total mean values are gradually and significantly decreased in patients ranging from MCI to severe AD, when compared to the controls [41]. In a systematic review and meta-analysis, Thomson et al. [39] identified five studies including 214 MCI eyes and 421 control eyes), demonstrating a significant reduction in the overall mean RNFL thickness and in all four quadrants (superior, nasal, temporal and inferior) in patients with MCI. Therefore, as previously demonstrated, peripapillary RNFL and macular thickness parameters in MCI patients were significantly reduced when compared to normal controls. These measurements assessed by OCT demonstrate that axonal loss in MCI is situated in an intermediate stage between AD patients and healthy controls, suggesting the involvement of the retina in early phases even before the onset of dementia.

Conclusions

In summary, in this article we discussed several clinical applications of OCT in patients with AD. The peripapillary RNFL thickness measurements were reduced in all quadrants, suggesting that a diffuse axonal degeneration occurs in AD patients. This finding is reinforced by the macular thickness reduction, especially by the loss of inner retinal layers, which reflects a preferential retinal GCL impairment in patients with AD. Therefore, OCT parameters can be used to distinguish AD patients from normal aging. Both peripapillary and macular thickness measurements obtained by OCT can be used to detect early neuronal loss as demonstrated in MCI patients, suggesting that OCT could be a promising diagnostic tool in demential diseases. Future studies showing that OCT can be useful in identify the converting patients from MCI to AD are required. Moreover, neuronal loss seems to correlate well with cognitive impairment in AD, especially for macular parameters. This indicates the promising role of OCT in the clinical evaluation of these patients. Therefore, OCT is a non-invasive test, which we believe will serve as a biomarker in AD patients that could be routinely used to evaluate and follow these patients, allowing a more comprehensive approach in this disease.
  61 in total

1.  Macular thickness as a potential biomarker of mild Alzheimer's disease.

Authors:  Elena S Garcia-Martin; Blanca Rojas; Ana I Ramirez; Rosa de Hoz; Juan J Salazar; Raquel Yubero; Pedro Gil; Alberto Triviño; Jose M Ramirez
Journal:  Ophthalmology       Date:  2014-03-18       Impact factor: 12.079

2.  Early glaucoma involves both deep local, and shallow widespread, retinal nerve fiber damage of the macular region.

Authors:  Donald C Hood; Anastasia Slobodnick; Ali S Raza; Carlos Gustavo de Moraes; Christopher C Teng; Robert Ritch
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-03       Impact factor: 4.799

Review 3.  An anatomic substrate for visual disconnection in Alzheimer's disease.

Authors:  J H Morrison; P R Hof; C Bouras
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

4.  Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease.

Authors:  Anat Kesler; Veronika Vakhapova; Amos D Korczyn; Elvira Naftaliev; Meira Neudorfer
Journal:  Clin Neurol Neurosurg       Date:  2011-03-31       Impact factor: 1.876

5.  Retinal nerve fiber layer abnormalities in Alzheimer's disease.

Authors:  T R Hedges; R Perez Galves; D Speigelman; N R Barbas; E Peli; C J Yardley
Journal:  Acta Ophthalmol Scand       Date:  1996-06

6.  Relationship between optical coherence tomography, pattern electroretinogram and automated perimetry in eyes with temporal hemianopia from chiasmal compression.

Authors:  Mário L R Monteiro; Leonardo P Cunha; Luciana V F Costa-Cunha; Otacílio O Maia; Maria K Oyamada
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-05       Impact factor: 4.799

7.  Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography.

Authors:  Ermengarda Marziani; Simone Pomati; Paola Ramolfo; Mario Cigada; Andrea Giani; Claudio Mariani; Giovanni Staurenghi
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-05       Impact factor: 4.799

8.  A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss.

Authors:  Robert M Cohen; Kavon Rezai-Zadeh; Tara M Weitz; Altan Rentsendorj; David Gate; Inna Spivak; Yasmin Bholat; Vitaly Vasilevko; Charles G Glabe; Joshua J Breunig; Pasko Rakic; Hayk Davtyan; Michael G Agadjanyan; Vladimir Kepe; Jorge R Barrio; Serguei Bannykh; Christine A Szekely; Robert N Pechnick; Terrence Town
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

9.  Visual dysfunction in Alzheimer's disease: relation to normal aging.

Authors:  A Cronin-Golomb; S Corkin; J F Rizzo; J Cohen; J H Growdon; K S Banks
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

10.  Analysis of Retinal Peripapillary Segmentation in Early Alzheimer's Disease Patients.

Authors:  Elena Salobrar-Garcia; Irene Hoyas; Mercedes Leal; Rosa de Hoz; Blanca Rojas; Ana I Ramirez; Juan J Salazar; Raquel Yubero; Pedro Gil; Alberto Triviño; José M Ramirez
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

View more
  8 in total

1.  Peripapillary retinal nerve fiber layer and ganglion cell complex degeneration in Egyptian patients with bipolar disorder.

Authors:  Dalia H Khalil; Mohamed M Said
Journal:  Eye (Lond)       Date:  2019-03-29       Impact factor: 3.775

2.  Salvage of the retinal ganglion cells in transition phase in Alzheimer's disease with topical coenzyme Q10: is it possible?

Authors:  Refika Hande Karakahya; Tuba Şaziye Özcan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-28       Impact factor: 3.117

Review 3.  Patterns of Retinal Ganglion Cell Damage in Neurodegenerative Disorders: Parvocellular vs Magnocellular Degeneration in Optical Coherence Tomography Studies.

Authors:  Chiara La Morgia; Lidia Di Vito; Valerio Carelli; Michele Carbonelli
Journal:  Front Neurol       Date:  2017-12-22       Impact factor: 4.003

Review 4.  Optical Coherence Tomography in Alzheimer's Disease and Other Neurodegenerative Diseases.

Authors:  Jonah Doustar; Tania Torbati; Keith L Black; Yosef Koronyo; Maya Koronyo-Hamaoui
Journal:  Front Neurol       Date:  2017-12-19       Impact factor: 4.003

5.  Functional and morphological changes of the retinal vessels in Alzheimer's disease and mild cognitive impairment.

Authors:  Giuseppe Querques; Enrico Borrelli; Riccardo Sacconi; Luigi De Vitis; Letizia Leocani; Roberto Santangelo; Giuseppe Magnani; Giancarlo Comi; Francesco Bandello
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

6.  Retinal oxygen metabolism in patients with mild cognitive impairment.

Authors:  Olof Birna Olafsdottir; Hrafnhildur Sif Saevarsdottir; Sveinn Hakon Hardarson; Kristin Hanna Hannesdottir; Valgerdur Dora Traustadottir; Robert Arnar Karlsson; Anna Bryndis Einarsdottir; Katrin Dilja Jonsdottir; Einar Stefansson; Jon Snaedal
Journal:  Alzheimers Dement (Amst)       Date:  2018-04-01

7.  Cohort profile: design and methods in the eye and vision consortium of UK Biobank.

Authors:  Sharon Yu Lin Chua; Dhanes Thomas; Naomi Allen; Andrew Lotery; Parul Desai; Praveen Patel; Zaynah Muthy; Cathie Sudlow; Tunde Peto; Peng Tee Khaw; Paul J Foster
Journal:  BMJ Open       Date:  2019-02-21       Impact factor: 2.692

8.  Optical Coherence Tomography to Assess Neurodegeneration in Phenylalanine Hydroxylase Deficiency.

Authors:  Amelie S Lotz-Havla; Katharina Weiß; Katharina Schiergens; Stephanie Regenauer-Vandewiele; Klaus G Parhofer; Tara Christmann; Luise Böhm; Joachim Havla; Esther M Maier
Journal:  Front Neurol       Date:  2021-12-10       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.